Colorectal Cancer

The investment bank said that Exact's Cologuard test continues to gain market share, and that its alternatives are largely invasive and inferior.

The company said its sales team will serve healthcare providers by telephone and online until it's safe to return to the field.

Researchers re-examined whole-genome and whole-transcriptome sequencing TCGA studies from 33 cancer types and found unique microbial signatures.

The government payor is interested in public input on the evidence underlying the blood-based PCR test.

The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon reproductive health tests.

The company said it will use the proceeds for general corporate purposes, such as the repayment of debt, working capital, and possible acquisitions.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 63 percent year over year.